Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + carboplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of the PD-1 inhibitor pembrolizumab and the cytotoxic chemotherapies carboplatin and paclitaxel. It is being evaluated by Wake Forest University Health Sciences as a first-line treatment for patients with metastatic head and neck squamous cell carcinoma (HNSCC) who are ineligible for 5-fluorouracil (5-FU). Pembrolizumab is a humanized monoclonal antibody that enhances the immune response against tumor cells by blocking the PD-1/PD-L1 pathway. Carboplatin is a platinum-based agent that induces DNA damage through cross-linking, while paclitaxel is a taxane that inhibits cell division by stabilizing microtubules. This regimen aims to provide an effective alternative to standard-of-care fluorouracil-based therapies for patients with contraindications to 5-FU.
- Brand names
- KeytrudaParaplatinTaxol
- Other names
- pembrolizumab plus carboplatin and paclitaxel
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on pembrolizumab + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + carboplatin + paclitaxel.